SERES THERAPEUTICS INC (MCRB) Fundamental Analysis & Valuation

NASDAQ:MCRB • US81750R2013

Current stock price

8.32 USD
-0.39 (-4.48%)
Last:

This MCRB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. MCRB Profitability Analysis

1.1 Basic Checks

  • In the past year MCRB has reported negative net income.
  • In the past year MCRB had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: MCRB reported negative net income in multiple years.
  • In multiple years MCRB reported negative operating cash flow during the last 5 years.
MCRB Yearly Net Income VS EBIT VS OCF VS FCFMCRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M -200M -250M

1.2 Ratios

  • With an excellent Return On Assets value of 4.12%, MCRB belongs to the best of the industry, outperforming 90.14% of the companies in the same industry.
  • MCRB has a Return On Equity of 12.88%. This is amongst the best in the industry. MCRB outperforms 92.84% of its industry peers.
Industry RankSector Rank
ROA 4.12%
ROE 12.88%
ROIC N/A
ROA(3y)-9.16%
ROA(5y)-23.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MCRB Yearly ROA, ROE, ROICMCRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K

1.3 Margins

  • Looking at the Profit Margin, with a value of 721.93%, MCRB belongs to the top of the industry, outperforming 99.23% of the companies in the same industry.
  • The Operating Margin and Gross Margin are not available for MCRB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 721.93%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MCRB Yearly Profit, Operating, Gross MarginsMCRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. MCRB Health Analysis

2.1 Basic Checks

  • MCRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MCRB has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, MCRB has more shares outstanding
  • MCRB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MCRB Yearly Shares OutstandingMCRB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
MCRB Yearly Total Debt VS Total AssetsMCRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • MCRB has an Altman-Z score of -11.32. This is a bad value and indicates that MCRB is not financially healthy and even has some risk of bankruptcy.
  • MCRB has a worse Altman-Z score (-11.32) than 75.63% of its industry peers.
  • There is no outstanding debt for MCRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -11.32
ROIC/WACCN/A
WACC9.19%
MCRB Yearly LT Debt VS Equity VS FCFMCRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M -200M

2.3 Liquidity

  • MCRB has a Current Ratio of 2.56. This indicates that MCRB is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.56, MCRB is doing worse than 69.44% of the companies in the same industry.
  • A Quick Ratio of 2.56 indicates that MCRB has no problem at all paying its short term obligations.
  • MCRB has a worse Quick ratio (2.56) than 67.12% of its industry peers.
Industry RankSector Rank
Current Ratio 2.56
Quick Ratio 2.56
MCRB Yearly Current Assets VS Current LiabilitesMCRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MCRB Growth Analysis

3.1 Past

  • MCRB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.71%, which is quite impressive.
  • MCRB shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -52.67% yearly.
EPS 1Y (TTM)68.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y-52.67%
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, MCRB will show a very negative growth in Earnings Per Share. The EPS will decrease by -19.79% on average per year.
  • MCRB is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y-38.3%
EPS Next 2Y-24.13%
EPS Next 3Y-19.79%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MCRB Yearly Revenue VS EstimatesMCRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2025 50M 100M 150M
MCRB Yearly EPS VS EstimatesMCRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

2

4. MCRB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MCRB. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MCRB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MCRB Price Earnings VS Forward Price EarningsMCRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

  • 90.91% of the companies in the same industry are more expensive than MCRB, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 92.24
EV/EBITDA N/A
MCRB Per share dataMCRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6 -8

4.3 Compensation for Growth

  • MCRB's earnings are expected to decrease with -19.79% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.13%
EPS Next 3Y-19.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MCRB Dividend Analysis

5.1 Amount

  • MCRB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MCRB Fundamentals: All Metrics, Ratios and Statistics

SERES THERAPEUTICS INC

NASDAQ:MCRB (4/10/2026, 8:00:01 PM)

8.32

-0.39 (-4.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-05
Inst Owners25.66%
Inst Owner Change0%
Ins Owners0.45%
Ins Owner Change0.7%
Market Cap79.79M
Revenue(TTM)789.00K
Net Income(TTM)5.70M
Analysts82.86
Price Target22.44 (169.71%)
Short Float %7.45%
Short Ratio8.86
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.35%
Min EPS beat(2)-28%
Max EPS beat(2)17.29%
EPS beat(4)2
Avg EPS beat(4)-109.35%
Min EPS beat(4)-437.4%
Max EPS beat(4)17.29%
EPS beat(8)5
Avg EPS beat(8)-49.43%
EPS beat(12)7
Avg EPS beat(12)-30.55%
EPS beat(16)7
Avg EPS beat(16)-25.76%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.76%
PT rev (3m)4.76%
EPS NQ rev (1m)-7.43%
EPS NQ rev (3m)-7.43%
EPS NY rev (1m)5.18%
EPS NY rev (3m)5.18%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 101.13
P/FCF 92.24
P/OCF 71.43
P/B 1.8
P/tB 1.8
EV/EBITDA N/A
EPS(TTM)-6.07
EYN/A
EPS(NY)-8.39
Fwd EYN/A
FCF(TTM)0.09
FCFY1.08%
OCF(TTM)0.12
OCFY1.4%
SpS0.08
BVpS4.61
TBVpS4.61
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 4.12%
ROE 12.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 721.93%
GM N/A
FCFM 109.63%
ROA(3y)-9.16%
ROA(5y)-23.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 6.1%
Cap/Sales 31.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 15.19%
Current Ratio 2.56
Quick Ratio 2.56
Altman-Z -11.32
F-Score6
WACC9.19%
ROIC/WACCN/A
Cap/Depr(3y)46.93%
Cap/Depr(5y)89.96%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11%
EPS Next Y-38.3%
EPS Next 2Y-24.13%
EPS Next 3Y-19.79%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y-52.67%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y25.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.97%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y100.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y100.75%
OCF growth 3YN/A
OCF growth 5YN/A

SERES THERAPEUTICS INC / MCRB Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SERES THERAPEUTICS INC (MCRB) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MCRB.


What is the valuation status for MCRB stock?

ChartMill assigns a valuation rating of 2 / 10 to SERES THERAPEUTICS INC (MCRB). This can be considered as Overvalued.


How profitable is SERES THERAPEUTICS INC (MCRB) stock?

SERES THERAPEUTICS INC (MCRB) has a profitability rating of 3 / 10.


How financially healthy is SERES THERAPEUTICS INC?

The financial health rating of SERES THERAPEUTICS INC (MCRB) is 5 / 10.


Can you provide the expected EPS growth for MCRB stock?

The Earnings per Share (EPS) of SERES THERAPEUTICS INC (MCRB) is expected to decline by -38.3% in the next year.